Vanguard Group Inc. Purchases 317,538 Shares of Corteva, Inc. $CTVA

Key Points

• Vanguard Group increased its Corteva stake by 0.4% in Q4, buying 317,538 shares to hold 80,536,951 shares — about 11.92% of the company worth roughly $5.40 billion.
• Insider Brian Titus sold 8,311 shares on Feb. 20 (about $636,207), cutting his holding by 50.67% to 8,090 shares; corporate insiders now own about 0.15% of Corteva.
• Analysts give Corteva a consensus rating of “Moderate Buy” with an average price target of $85.19 (several firms have recently raised targets), and the company set FY2026 EPS guidance of 3.450–3.700.

Vanguard Group Inc. lifted its stake in shares of Corteva, Inc. (NYSE:CTVA - Free Report) by 0.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 80,536,951 shares of the company's stock after buying an additional 317,538 shares during the period. Vanguard Group Inc. owned about 11.92% of Corteva worth $5,398,392,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Brighton Jones LLC raised its position in Corteva by 307.2% in the fourth quarter. Brighton Jones LLC now owns 15,588 shares of the company's stock valued at $888,000 after purchasing an additional 11,760 shares during the last quarter. Woodline Partners LP increased its stake in shares of Corteva by 40.3% in the first quarter. Woodline Partners LP now owns 57,919 shares of the company's stock valued at $3,645,000 after buying an additional 16,644 shares during the period. EverSource Wealth Advisors LLC boosted its position in Corteva by 62.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,559 shares of the company's stock worth $191,000 after buying an additional 980 shares during the period. Cresset Asset Management LLC grew its holdings in Corteva by 2.6% during the 2nd quarter. Cresset Asset Management LLC now owns 7,063 shares of the company's stock worth $526,000 after acquiring an additional 181 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Corteva during the 2nd quarter worth approximately $1,464,000. Institutional investors and hedge funds own 81.54% of the company's stock.

Insider Buying and Selling at Corteva

In other news, insider Brian Titus sold 8,311 shares of the company's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $76.55, for a total transaction of $636,207.05. Following the transaction, the insider owned 8,090 shares in the company, valued at approximately $619,289.50. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.15% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. CICC Research raised their price target on shares of Corteva from $70.00 to $80.00 and gave the company an "outperform" rating in a research note on Wednesday, February 11th. Argus increased their price objective on Corteva from $80.00 to $91.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Weiss Ratings restated a "hold (c)" rating on shares of Corteva in a report on Wednesday, April 22nd. Mizuho increased their price objective on Corteva from $82.00 to $94.00 and gave the company an "outperform" rating in a report on Wednesday, April 15th. Finally, Zacks Research downgraded Corteva from a "strong-buy" rating to a "hold" rating in a report on Friday, February 20th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, Corteva currently has a consensus rating of "Moderate Buy" and an average price target of $85.19.

Corteva Price Performance

CTVA stock opened at $79.53 on Tuesday. The firm has a market cap of $53.39 billion, a price-to-earnings ratio of 50.34, a PEG ratio of 2.74 and a beta of 0.68. The company has a quick ratio of 0.96, a current ratio of 1.43 and a debt-to-equity ratio of 0.07. Corteva, Inc. has a 12-month low of $60.53 and a 12-month high of $85.63. The company's fifty day simple moving average is $80.19 and its 200 day simple moving average is $71.82.

Corteva (NYSE:CTVA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting the consensus estimate of $0.22. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business earned $0.32 earnings per share. The business's quarterly revenue was down 1.7% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts expect that Corteva, Inc. will post 3.62 earnings per share for the current year.

Corteva Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 16th. Stockholders of record on Monday, March 2nd were issued a dividend of $0.18 per share. The ex-dividend date was Monday, March 2nd. This represents a $0.72 annualized dividend and a dividend yield of 0.9%. Corteva's dividend payout ratio is currently 45.57%.

About Corteva

Corteva, Inc NYSE: CTVA is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva's operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.